A detailed history of Eagle Bay Advisors LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 149 shares of SUPN stock, worth $5,337. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149
Previous 229 34.93%
Holding current value
$5,337
Previous $6,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$25.77 - $35.16 $2,061 - $2,812
-80 Reduced 34.93%
149 $4,000
Q2 2024

Jul 26, 2024

SELL
$25.99 - $33.85 $1,455 - $1,895
-56 Reduced 19.65%
229 $6,000
Q1 2024

May 08, 2024

SELL
$27.11 - $35.17 $3,144 - $4,079
-116 Reduced 28.93%
285 $9,000
Q4 2023

Feb 08, 2024

SELL
$22.72 - $29.68 $63,865 - $83,430
-2,811 Reduced 87.52%
401 $11,000
Q3 2023

Nov 13, 2023

BUY
$27.57 - $32.91 $27,128 - $32,383
984 Added 44.17%
3,212 $88,000
Q2 2023

Aug 10, 2023

SELL
$29.91 - $38.73 $17,108 - $22,153
-572 Reduced 20.43%
2,228 $66,000
Q1 2023

Apr 24, 2023

SELL
$34.93 - $42.03 $13,482 - $16,223
-386 Reduced 12.12%
2,800 $101,000
Q4 2022

Jan 26, 2023

BUY
$31.09 - $37.88 $16,011 - $19,508
515 Added 19.28%
3,186 $0
Q3 2022

Nov 22, 2022

BUY
$28.79 - $35.41 $230 - $283
8 Added 0.3%
2,671 $91,000
Q2 2022

Aug 19, 2022

BUY
$25.33 - $34.25 $39,692 - $53,669
1,567 Added 142.97%
2,663 $77 Million
Q1 2022

May 11, 2022

SELL
$28.51 - $32.9 $9,921 - $11,449
-348 Reduced 24.1%
1,096 $35,000
Q4 2021

Jan 21, 2022

BUY
$26.37 - $34.22 $19,777 - $25,665
750 Added 108.07%
1,444 $42,000
Q3 2021

Nov 12, 2021

SELL
$23.54 - $31.39 $11,511 - $15,349
-489 Reduced 41.34%
694 $18,000
Q2 2021

Jul 30, 2021

BUY
$26.72 - $33.19 $31,609 - $39,263
1,183 New
1,183 $39,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.92B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.